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Reduction of native prion protein (PrP) levels in the brain is an attractive and genetically 
validated strategy for the treatment or prevention of human prion diseases. Development of any 
PrP-reducing therapeutic will require an appropriate pharmacodynamic biomarker: a practical 
and robust method for quantifying PrP, and reliably demonstrating its reduction, in the CNS of a 
living patient. Here we evaluate the potential of enzyme-linked immunosorbent assay (ELISA)-
based quantification of human PrP in human cerebrospinal fluid (CSF) to serve as a biomarker 
for PrP-reducing therapeutics. We show that CSF PrP is highly sensitive to plastic adsorption 
during handling and storage, but its loss can be minimized by addition of detergent. We find that 
blood contamination does not affect CSF PrP levels, and CSF PrP and hemoglobin are 
uncorrelated, together suggesting that CSF PrP is CNS-derived, supporting its relevance for 
monitoring the tissue of interest and in keeping with high PrP abundance in brain relative to 
blood. In a cohort with controlled sample handling, CSF PrP exhibits good test-retest reliability 
(mean coefficient of variation 13% over 8-11 weeks), suggesting that therapeutically meaningful 
reductions in brain PrP could be readily detected in CSF. Together, these findings supply a 
method for monitoring the effect of a PrP-reducing drug in the CNS, which will be critical to the 
development of any prion therapeutic with this mechanism of action. 






Prion disease — a fatal and untreatable neurodegenerative disease — is caused by misfolding 
of the prion protein (PrP), encoded by the gene PRNP1. PrP is a well-validated drug target for 
prion disease: knockout animals are invulnerable to prion infection2, heterozygous knockouts 
have delayed onset of disease3, and post-natal depletion of PrP can delay or prevent prion 
disease4,5. Total knockout is tolerated in mice6,7, cows8, and goats9,10, and healthy humans with 
one loss-of-function allele of PRNP have been identified11. Therefore, candidate therapies for 
prion disease may seek to lower PrP levels in the brain. 
 
Clinical trials of such therapies will be enhanced by early determination of whether PrP is indeed 
being lowered effectively at a tolerated dose. The brain is the only tissue with a known 
phenotype in prion disease, and is therefore the target tissue for any therapeutic, but it is not 
realistic to perform serial brain biopsies to quantify PrP in brain tissue. Instead cerebrospinal 
fluid (CSF), produced in the brain by the choroid plexus and obtainable through a lumbar 
puncture (LP), provides a reasonable alternative. CSF is reasonably accessible in living patients 
and more reflective of the CNS milieu than peripheral tissues or fluids. PrP is known to be 
detectable in CSF at levels ranging from tens to hundreds of ng/mL, within the range of 
standard protein detection assays including the commonly used BetaPrion Human ELISA 
assay12,13. Here, we chart the technical parameters of this assay, and use it to establish the 





1. The BetaPrion Human PrP ELISA quantifies total CSF PrP reproducibly, precisely, 
sensitively and selectively. 
 
Multiple groups have reported successful detection of PrP in human CSF using ELISA assays, 
including the one currently commercially available human PrP ELISA kit, the BetaPrion ELISA 
assay12–16. This sandwich ELISA is configured in 96-well format and relies on an apparently 
conformational human PrP (HuPrP) capture antibody and a horseradish peroxidase (HRP)-
conjugated primary detection antibody to HuPrP residues 151-18013. The assay is best 
described as measuring total PrP, which is the variable of interest for PrP-lowering therapeutics 
(see Discussion). 
 
The standard of validation required for a ligand-binding assay to be used in the context of 
clinical drug development is more stringent than for a research context, as described in FDA’s 
2013 Draft Guidance on Bioanalytical Method Validation17. To this end, we assessed this 
assay’s precision, sensitivity, selectivity and reproducibility by analyzing N=225 human CSF 
samples from symptomatic prion disease patients, pre-symptomatic prion disease mutation 
carriers, non-prion dementia patients, and normal pressure hydrocephalus (NPH) patients as 
well as controls (Table S1) across 41 plates. The results broadly support the technical suitability 
of this assay for reliable quantification of CSF PrP (Table 1 and Figure S1).  
 
In assessing within-plate variability we discerned plate position effects for control samples, with 
a downward trend from upper left to lower right, suggesting that samples intended to be 
compared should be co-located on the ELISA plate, and/or that plate position should be 
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adjusted for using standard curves or control samples (Figure S2). Comparison of the kit 
standard curve to a standard curve made from recombinant human prion protein quantified by 
amino acid analysis (AAA) suggests that the kit may be most useful for relative rather than 
absolute quantification of PrP (Figure S3B).  
 
Experiment Results 
Within-plate technical replicate 
reproducibility (same dilution) 
CV = 8% 
Within-plate technical replicate 
reproducibility (all dilutions) 
CV = 11% 
Between-plate technical replicate 
reproducibility 
CV = 22% in control sample v1205.6 across 6 plates 
run on different days. 
Sensitivity LLOQ is 3-5× the blank signal, depending on the 
platereader used. 
Selectivity Non-reactive for recombinant mouse PrP, rat CSF 
and cynomolgus monkey CSF (consistent with one 
amino acid mismatch in the reported detection 
antibody epitope13), artificial CSF and protease-
digested CSF. 
Dilution linearity Linear across two samples and five dilutions. See 
figure S1A. 
Spike recovery Using AAA-quantified recombinant HuPrP23-230 as 
a standard, spike recovery of recombinant PrP in 
CSF was 90% across five concentrations. Titration of 
a high PrP CSF sample into a low PrP sample 
resulted in linear recovery. See Figure S3. 
Standard curve reproducibility CV < 10% at all six non-zero standard curve points, 
across five replicates. See Figure S1. 
 
Table 1. The BetaPrion human PrP ELISA assay technically supports reliable quantification of 
PrP in human CSF.  
 
 
2. Standardized storage and handling are essential to reliable quantification of CSF 
PrP. 
 
Consistent with previous reports, we observed over two orders of magnitude of variability of 
CSF PrP levels between samples (Fig S4A). Despite this large range, PrP was measurable by 
ELISA in all CSF samples analyzed, including in CSF from individuals with 13 different prion 
disease mutations (Fig S4A-B, Table 1). PrP was reduced in individuals with symptomatic prion 
disease, as previously reported12–14,16,18, but still varied by approximately an order of magnitude 
within any one diagnosis (Fig S4A). PrP also differed significantly between the various cohorts 
included in our study (Fig S4B), but the variance within cohorts was dramatic (mean ~30-fold 
difference between highest and lowest sample within a cohort). CSF PrP was correlated with 
age (Fig S4C), but among our samples age is confounded with cohort, diagnosis, and likely 
many unobserved variables, making it unclear whether this correlation is biologically 
meaningful. CSF PrP did not differ according to sex (Fig S4D), and exhibited no lumbar-thoracic 
gradient (Fig S4E). After noticing that PrP levels appeared lower in smaller aliquots of the same 
CSF sample (Fig S5A), we hypothesized that differences in sample handling might be a major 
source of variability in observed CSF PrP levels. 




CSF PrP’s stability under different handling conditions has not previously been systematically 
assessed, but it is known that other neurodegenerative disease-associated amyloidogenic 
proteins have a high affinity for plastics19,20. To assess PrP’s susceptibility to differential CSF 
sample handling, we subjected aliquots of a single CSF sample to variations in storage 
temperature, number of freeze-thaw cycles, storage aliquot size, number of transfers between 
polypropylene storage tubes, and amount of exposure to polypropylene pipette tips (Figure 1A). 
Strikingly, increased plastic exposure in the latter three conditions dramatically reduced 
measurable PrP in solution (Figure 1A). To promote PrP solubility in our samples, we 
experimented with adding small amounts of CHAPS, a common zwitterionic surfactant known to 
enhance protein solubility in multiple contexts21–23. Addition of 0.03% CHAPS prior to aliquotting 
minimized PrP loss to plastic across most manipulations (Figure 2A). For instance, transferring 
a CSF sample to a new microcentrifuge tube three times eliminated at least 73% of detectable 
PrP (P < 1 × 10-6, two-sided t test) without CHAPS, but only 7.1% (P = 0.37) of PrP was lost in 
the presence of 0.03% CHAPS. Addition of CHAPS also increased total PrP recovery, 
presumably by preventing loss to the single polypropylene tube and tips used for plating 
samples (Figure S5), and was effective against loss to multiple plastics but not glass (Figure 
1C). 
 
Storing CSF at room temperature for 24 hours and subjecting samples to three freeze-thaw 
cycles reduced PrP even in the presence of detergent (Figure 1A-B). From this we conclude 
that time at room temperature and number of freeze-thaw cycles for CSF samples should be a) 
minimized, b) closely tracked for all samples, and c) standardized for samples across which PrP 
levels will be compared.  
 
We also investigated the relationship between measured PrP and total protein in N=217 
samples, using the DC total protein assay. Across all samples analyzed, a modest correlation (r 
= 0.36, Spearman rank test, P = 6.2 × 10-8) between PrP and total protein was observed, which 
may reflect either a biological phenomenon, or simply the ability of higher ambient protein levels 
to serve a blocking function that partially offsets PrP loss by adsorption. In support of the latter 
interpretation, addition to CSF of 1 mg/mL bovine serum albumin increased recovery of PrP 
(Figure S5F), though it was less effective than CHAPS at preventing loss due to transfers. 
 
Overall, these data emphasize the importance of consistent handling of CSF samples intended 
for comparative PrP quantification, and support preventative addition of detergent as a means to 
prevent otherwise massively confounding PrP loss to storage and handling surfaces (see 
Discussion).   
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Figure 1. Storage and handling can dramatically reduce the amount of PrP detected in 
CSF samples unless appropriate measures are taken. A. Increased polypropylene exposure 
substantially reduces detectable PrP. B. Addition of 0.03% CHAPS detergent to samples 
increases PrP recovery and consistently mitigates PrP loss to plastic. C. Addition of CHAPS 
(bottom) increases total PrP recovery and shows similar rescue across plastics, but substantial 
PrP loss is still observed upon storage in glass. D. Across 217 CSF samples, total protein levels 
and PrP levels were modestly correlated (Spearman’s rank correlation coefficient = 0.36, 
P=6.2×10-8). In A-C, dots represent mean and line segments represent 95% confidence 
intervals across 4 to 7 aliquots of the same sample, each measured in duplicate at a 1:50 
dilution. In D, dots represent mean of measurements within dynamic range, among 2 dilutions 
with 2 technical replicates each. 
 
 
3. PrP in CSF is CNS-derived and unlikely to be confounded by blood contamination. 




CSF PrP is an informative tool in prion disease only insofar as it is a faithful proxy for PrP levels 
in the CNS, the relevant target for any future therapeutic including those with a PrP-lowering 
mechanism. CSF proteins derive from two major sources, CNS and blood, with proportional 
contribution driven by relative tissue abundance of a given protein24. Blood proteins enter CSF 
either through the trauma of lumbar puncture or through gradual diffusion through the dura as 
CSF flows down the spinal canal25,26. To assess the contribution of blood-derived PrP to overall 
CSF PrP, we compared PrP levels across brain samples and red blood cell, buffy coat and 
plasma fractions of blood from non-neurodegenerative disease control individuals, versus all of 
the CSF samples in our study (Figure 2A). Among blood fractions, PrP was most consistently 
detected in buffy coat, in keeping with reports that blood PrP emanates chiefly from 
platelets27,28; we also detected PrP above the lower limit of quantification in some red cell 
samples, but never in plasma. As the average PrP concentration in all three blood fractions was 
still well below that in brain and was lower than that in 96% of CSF samples analyzed, the risk 
of confounding signal from blood-derived PrP appears negligible. Consistent with this 
conclusion, spiking whole blood into CSF at up to 1% (v/v) did not increase the detected PrP 
(Figure 2B). Finally, as a proxy for blood contamination we measured hemoglobin levels in 
N=128 CSF samples and observed no correlation between CSF hemoglobin and CSF PrP 
(Figure 2C). Variation in hemoglobin levels also failed to confound the test-retest reliability of 
CSF PrP (Figure S6). From these lines of evidence we conclude that the PrP detected in CSF is 
overwhelmingly derived from the CNS. 
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Figure 2. Blood PrP contributes negligibly to the PrP detected in CSF. A. PrP is abundant 
in a range of human brain regions, undetectable in human plasma, and is detectable in the red 
cell and buffy coat fractions only at low levels compared to PrP in CSF. B. Spiking whole blood 
into CSF up to 1% by volume does not impact measured PrP. C. Hemoglobin and PrP levels in 
CSF are uncorrelated. In A and C, dots represent mean of measurements within dynamic range, 
among 2 technical replicates per dilution. In A-C, dots represent mean and line segments 
represent 95% confidence intervals across 2 to 3 aliquots of the same sample. 
 
4. CSF PrP is stable on test-retest. 
 
Across N=225 samples analyzed, CSF PrP levels ranged over two orders of magnitude (1.9 – 
593.6 ng/mL), consistent with previous reports12,13, but our findings above (Figure 1) suggest 
that much variability might arise from differences in sample handling. In order for CSF PrP 
levels to serve as a meaningful biomarker, they must be stable enough in one individual over 
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time that a drug-dependent reduction could be reliably detected. We quantified PrP in test-retest 
CSF samples collected from nine individuals — placebo-treated controls with non-prion 
dementia — who had undergone two fasting morning lumbar punctures at 8-11 week intervals in 
the context of a clinical trial29. LPs were performed according to a standardized protocol by a 
single investigator, and samples were subsequently processed uniformly. Under these highly 
controlled conditions, the mean CV between timepoints for a given participant was agreeably 
low at 13% (Figure 3). Higher CVs of 33% - 41% were observed in three other cohorts where 
sample handling appears to have been less uniform (Supplementary Discussion and Figure S7).  
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Figure 3. Test-retest stability of CSF PrP. Uniformly processed CSF samples were provided 
from a past clinical trial, from placebo-treated individuals with mild, non-prion cognitive 
impairment. Fasting morning lumbar punctures were performed by one investigator on nine 
individuals then repeated at an interval of 8-11 weeks. Dots represent means, and line 
segments 95% confidence intervals, of measurements within dynamic range among 2 dilutions 






Here we present evidence supporting CSF PrP quantification as a tool for clinical trials of PrP-
lowering therapeutics. We establish that CSF PrP is sensitive to multiple factors that may be 
encountered during handling and processing, and that the addition of 0.03% CHAPS detergent 
mitigates the most dramatic such factor by minimizing PrP loss to plastic. With use of 
appropriate protocols, CSF PrP can be measured reproducibly and with favorable test-retest 
reliability, with a mean CV of 13% over 8-11 weeks in one cohort.  CSF PrP is CNS-derived, 
rather than blood-derived, suggesting it should change in response to lowering of PrP in the 
brain.  




The above attributes suggest that CSF PrP will be a useful pharmacodynamic biomarker in the 
development of PrP-lowering therapeutics. However, our findings regarding PrP’s sensitivity to 
handling and processing factors demonstrate that an optimized protocol for CSF collection and 
processing will need to be closely followed for samples to be meaningfully compared. To this 
end, the protocol we are now using to collect such samples is detailed in Figure S8. For 
maximum protection of PrP from plastic adsorption, we propose addition of 0.03% CHAPS 
immediately upon transfer of CSF from the initial lumbar puncture syringe, prior to aliquotting or 
freezing. Detergent type and level were chosen for compatibility with our downstream ELISA 
and mass spectrometry assays. As shown in Figure S8, we are reserving aliquots of CSF 
without additive for future use in detergent-incompatible assays, but do not recommend use of 
such aliquots for PrP quantification. 
 
As previously mentioned, PrP levels in CSF as measured by ELISA have been reported to be 
reduced by on the order of half in symptomatic prion disease patients12,13,16, and this 
phenomenon is reflected in our samples as well (Figure S4). Multiple plausible biological 
mechanisms could explain these findings: incorporation of PrP into insoluble plaques30,31, 
internalization of misfolded PrP in the endosomal-lysosomal pathway32, and post-translational 
downregulation of PrP as a function of disease33. It is therefore possible that an intrinsic 
reduction in CSF PrP in the course of symptomatic disease could confound the use of PrP as a 
biomarker for the activity of PrP-lowering drug tested in a symptomatic population. While it is 
important to be aware of this potential limitation, symptomatic patients are not the population 
most in need of such a biomarker, as other tools exist to assess drug activity and efficacy in 
symptomatic patients. In particular, the signature rapid clinical decline associated with active 
disease has enabled several previous clinical trials to be conducted in symptomatic cohorts 
based on cognitive or survival endpoints34–40. Instead, the population best positioned to benefit 
from a CSF PrP pharmacodynamic biomarker in conjunction with a PrP-lowering drug is the 
population of presymptomatic individuals carrying high-penetrance genetic prion disease 
mutations. Our experiments to date confirm that PrP is measurable in carriers across a variety 
of mutations.. Our observations here support the hypothesis that target engagement and 
achievement of a meaningful proximal biological effect by a PrP-lowering drug candidate could 
be observed through quantification of PrP in CSF from serial lumbar punctures in such 
individuals, a hypothesis that will need to be tested in a clinical trial once such a drug candidate 
is available. 
 
Our study has several limitations. First, ELISA relies upon two epitopes being present and 
properly folded, and is thus vulnerable to confounding from misfolding or native proteolytic 
events. We are presently working to develop a targeted mass spectrometry-based orthogonal 
method for CSF total PrP quantification. Second, although we have established that CSF PrP is 
quantifiable in genetic prion disease patients and has good test-retest reliability in a cohort of 
patients with non-prion dementia, when we embarked on the present study we did not have 
access to short-term test-retest samples from presymptomatic genetic prion disease patients. 
To address this shortfall, in summer 2017 we launched a clinical research study at 
Massachusetts General Hospital to recruit presymptomatic individuals with PRNP mutations, 
and controls, for two lumbar punctures at an 8- to 16-week interval41. This study is following the 
collection and processing protocol specified in Figure S8. We hypothesize that with this protocol 
in place, test-retest reliability in this population will prove sufficient to enable future clinical trials 
monitoring CSF PrP before and after administration of a PrP-lowering drug. Third, the samples 
analyzed here were re-used after collection for other research or clinical purposes, meaning that 
in most cases we cannot fully account for how the samples were handled prior to our receipt of 
them. Thus, our numbers may exaggerate the inter-individual variation in CSF PrP in the 
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population. The question of whether the large observed inter-individual variability in PrP CSF 
levels indicates true biological variability or handling artifacts will be addressed by the uniformly 
processed samples currently being collected through our clinical study.  
 
In recent studies of proposed Alzheimer's disease and Huntington's disease biomarkers, the 
goal has been detection of a pathological molecule such as Aβ oligomers or mutant Huntingtin 
protein that is thought to be causative or indicative of the disease process20,42. Our goal differs 
in that native PrP is present in all humans, and is not itself a pathogenic species indicative of 
disease; it is present and measurable in healthy individuals. PrP is an attractive drug target in 
prion disease because it is shared among all prion disease subtypes, unifying what are 
otherwise ultra-orphan subsets of an already rare disease. Unlike the misfolded prions that 
derive from PrP and ultimately act as the pathogen in prion disease, PrP is structurally well-
characterized and can be targeted genetically; approaches to protectively reducing its levels 
could intervene at the level of DNA, RNA or protein. Our findings should empower clinical 
development towards the overdue realization of this well-supported therapeutic hypothesis.  
 
Moreover, this biomarker may help to empower a heretofore-unexplored route for drug 
development and trials in healthy, at-risk individuals. The increasing availability of large genetic 
datasets is enabling ever-more-refined estimates of the penetrance associated with disease-
associated PRNP mutations11. Individuals facing 90% or greater lifetime risk of genetic prion 
disease can be reliably identified years or decades in advance of onset. Such carriers lack any 
overt phenotype, and to date no reliable change indicative of prodromal disease has been 
systematically detected in this population by imaging or biochemical analysis. In addition, even if 
such a marker were to be found, it would be useful only once the prodromal disease process 
were already underway, when the greatest opportunity for meaningful intervention in at-risk 
individuals may have already passed. Preclinical evidence strongly indicates that regardless of 
mechanism of action, the potency of anti-prion therapeutics scales with time of intervention 
relative to disease course, with prophylactic administration prior to any molecular pathology 
offering greater benefit in delaying disease43–46. In the context of prevention trials in healthy 
carriers, it is possible that CSF PrP will be critical not just as a marker of target engagement, but 
as a surrogate endpoint. Because following pre-symptomatic individuals to a clinical endpoint 
appears infeasible47, lowering CSF PrP has been proposed as a surrogate endpoint meriting 
Accelerated Approval48. Continued study of CSF PrP will be critical to steering future treatment 
trials towards a preventative paradigm and to honoring the precious opportunity for preemptive 







Cerebrospinal fluid samples. De-identified human CSF samples were provided by multiple 
clinical collaborators and included both unpublished and previously published cohorts29,49. 
Samples were shipped on dry ice and stored at -80°C. Prior to use, samples were thawed on ice 
and centrifuged at 2,000 × g (at 4°C). Ninety percent of the volume was pipetted into a new tube 
to separate supernatant from cellular or other debris, aliquotted into new polypropylene storage 
tubes and refrozen at -80°C. For indicated samples, 0.03% CHAPS detergent by volume (final 
concentration) was pre-loaded into the supernatant receiving tube prior to the post-
centrifugation transfer, then mixed into the sample by gentle pipetting prior to aliquotting. 
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Quantification of human PrP in CSF, brain tissue and blood using the BetaPrion human PrP 
ELISA kit. Across experiments, PrP was quantified using the BetaPrion human PrP ELISA kit 
(Analytik Jena, cat no. 847-0104000104) according to the manufacturer’s instructions. In brief, 
samples were diluted into blocking buffer (5% BSA and 0.05% Tween-20 in PBS, filtered prior to 
use) at concentrations ranging from 1:100 to neat depending on the anticipated PrP content of 
the sample type. Unknown CSF samples were run at two dilutions each (typically 1:10 and 
1:50). Only one out of 225 CSF samples analyzed fell below the range of the assay’s lower limit 
of detection (1 ng/mL) at a 1:10 dilution, and was re-run neat, yielding a result of 1.9 ng/mL. 
Human brain samples were obtained from the Massachusetts Alzheimer's Disease Research 
Center (ADRC; N=26 samples from 5 different individuals, representing diverse cortical and 
subcortical regions) and from the National Prion Disease Pathology Surveillance Center (N=2 
samples of frontal cortex from non-prion controls) homogenized in PBS with 0.03% CHAPS at 
10% weight/vol in 7mL tubes (Precellys no. KT039611307.7) using a MiniLys tissue 
homogenizer (Bertin no. EQ06404-200-RD000.0) for 3 cycles of 40 seconds at maximum 
speed. The resulting 10% brain homogenates were diluted 1:10 and 1:100 in blocking buffer for 
ELISA. 
Human blood fractions were obtained from Zen-Bio, 0.03% CHAPS was added, and samples 
were then mixed either by pipetting up and down or by homogenization in a MiniLys using the 
same protocol described above. Blood fractions were diluted 1:10 in blocking buffer for ELISA. 
All samples were plated in duplicate. Lyophilized standards and kit reagents were diluted fresh 
for same-day use, with the exception of wash buffer and blocking buffer, excess of which were 
stored at 4°C for reuse within 4 weeks. The assay format is 96-well comprised of twelve 
modular 8-well strips which enabled partial plates to be run in some cases. Following all add 
and incubation steps the absorption per well was read in either a SpectraMax or FluoStar 
Optima plate reader at 450 nm with 620 nm absorbance also monitored as baseline. Data was 
exported as a text file and analyzed in R.  
 
Negative controls. Rat and cynomolgous monkey CSF (BioReclamation IVT; two samples each 
from two separate animals) and artificial CSF (Tocris no. 3525) were aliquotted and stored at -
80°C. For protease-digested CSF, two CSF samples with 0.03% CHAPS (measured to contain 
273 and 643 ng/mL PrP undigested) were digested with 5 ug/mL Proteinase K (WW Grainger 
Co. cat. no. 5000186667) at 37C for 1 hour, after which the digestion was halted with 4 mM 
PefaBloc (Sigma Aldrich cat. no. 11429868001) immediately prior to use in ELISA. 
 
Recombinant prion protein purification. For spike-in experiments and attempted detection of 
mouse recombinant PrP, in-house purified recombinant full-length human prion protein and 
mouse prion protein were purified from E. coli using established vectors (a generous gift from 
Byron Caughey's laboratory at NIH Rocky Mountain Labs) according to established 
methods50,51. Protein concentration was determined by 280 nm absorbance on a NanoDrop, and 
by amino acid analysis (AAA) performed in duplicate (New England Peptide) after the addition 
of 0.03% CHAPS. 
 
Storage and handling experiments. For all storage and handling experiments, each condition 
was run in parallel on four identical aliquots made from one original CSF sample, and each 
aliquot was plated in duplicate. For all transfer experiments, 40 µL CSF aliquots were thawed on 
ice, then the full volume was transferred to a new 500 µL storage tube the indicated number of 
times and allowed to sit for a minimum of fifteen minutes in each tube. Where not otherwise 
indicated, tubes were polypropylene.  
 
Total protein assay. The DC total protein assay (Bio-Rad cat. no. 5000111) was used according 
to the manufacturer’s instructions to measure total protein across 217 CSF samples. This 
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assay, similar in principle to a Lowry assay, combines the protein with an alkaline copper 
tartrate solution and Folin reagent52. The protein reacts with copper in the alkaline medium, then 
reduces the Folin reagent to yield species with a characteristic blue color in proportion to 
abundance of key amino acids including tyrosine and tryptophan. 
 
Blood fractions. Red blood cell, buffy coat, and plasma separated blood fractions from three 
separate individuals (Zen-Bio) were thawed, aliquotted, and refrozen before use to ensure lysis 
of cellular fractions. The BetaPrion human PrP ELISA was used to compare PrP levels these 
three blood fractions, two control human postmortem brain homogenate samples, and 156 
human CSF samples. Each sample was run in duplicate.  
 
Whole blood spike-in. Human whole blood (Zen-Bio) was spiked into parallel aliquots of a single 
CSF sample containing baseline mid-range PrP at 1%, 0.1%, or 0.01% per volume. EDTA 
spike-ins were performed in parallel to control for EDTA preservative carried in the blood 
sample. Samples were refrozen following spike-in then re-thawed for use to ensure lysis of 
cellular fractions prior to PrP quantification. 
  
Bethyl Laboratories Human Hemoglobin ELISA. Hemoglobin was quantified in 128 human CSF 
samples using the Human Hemoglobin ELISA kit (Bethyl Laboratories no. E88-134), according 
to the manufacturer’s instructions. Samples were diluted 1:10 and 1:100 for most experiments, 
an in some cases 1:20 and 1:100. All samples were plated in duplicate.  
 
Data and source code availability. All analyses were conducted using custom R scripts. Raw 
data from platereaders, associated metadata, and source code sufficient to reproduce the 
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Handling of test-retest samples.  
We analyzed test-retest reliability of CSF PrP in four cohorts (Figure S7). Here is what we know 
about the handling history of these samples: 
 Metformin trial placebo controls (Steven Arnold and Aaron Koenig). Mean CV = 13% 
(Figure 3 and Figure S7A). N=18 samples comprise 2 lumbar punctures from each of 9 
placebo-treated individuals from a randomized trial of metformin in individuals with mild 
cognitive impairment due to either Alzheimer disease or suspected non-amyloid 
pathology (SNAP). Test-retest interval ranges from 8 to 11 weeks. Lumbar punctures 
were performed fasting between 8:00a and 10:00a. CSF samples were handled 
according to a uniform protocol by the same staff, aliquotted into 0.5 mL aliquots within 1 
hour of collection and then frozen on dry ice before storage at -80°C. The aliquots we 
received, approximately 1.75 years after the last sample was collected, were all 0.25 mL, 
indicating another round of freeze/thaw and aliquotting had occurred in the interim, but 
all samples were received in identical tubes with identical labeling. 
 Sapropterin dihydrychloride participants (Kathryn Swoboda). Mean CV = 33% (Figure 
S7B). N=28 samples comprise 3 lumbar punctures from 8 individuals and 2 lumbar 
punctures from 2 individuals, all with Segawa syndrome (biallelic GCH1 loss-of-
function),enrolled in a trial monitoring effects of sapropterin dihydrochloride or placebo 
on CSF biomarkers. Test-retest interval ranges from 5 to 25 weeks. Lumbar punctures 
were performed at various times of day. Details of sample handling history are not 
known, but the aliquots we received were of various sizes (range: 150 μL to 1.3 mL) and 
were stored in different types of tubes (screw cap and flip top) with varied labeling 
(electronically generated and hand-written), suggesting a diverse sample handling 
history. 
 MIND lumbar drains (MGH MIND Tissue Bank). Mean CV = 40% (Figure S7C). N=18 
samples comprise 3 days of lumbar drains from 4 patients and 2 days of lumbar drains 
from 3 patients, with a test-retest interval ranging from 1 day to 4 monthsThese 
individuals were being treated at MGH for normal pressure hydrocephalus (N=7), C. 
dificile infection (N=1), or Herpes simplex infection (N=1). These in-patient lumbar drains 
had contact with diverse plastics for diverse amounts of time before freezing. In general, 
the samples passed through a pressure-measuring burette made of cellulose acetate 
propionate (CAP) before draining into a polyvinyl chloride (PVC) bag. CSF was later 
collected from the bag and frozen in either polystyrene (PS) or polypropylene (PP) 
tubes. Aliquots we received were of two different sizes: 0.5 mL and 4.0 mL. 
 Pre-symptomatic and symptomatic PRNP mutation carriers (Michael Geschwind). Mean 
CV=34% in each (Figure S7D-E). Samples were collected between 2009 and 2017 at 
two sites (UCSF Parnassus and subsequently UCSF Mission Bay) with multiple different 
physicians performing lumbar punctures according to a uniform protocol. Test-retest 
interval ranges from 2 months to 6 years. Samples were collected at various times of 
day and kept under refrigeration for variable amounts of time (ranging from a few hours 
to overnight) and then frozen at -80°C until being thawed and aliquotted by UCSF 
CoreLabs in the first half of 2017. No details are available on the degree of CSF plastic 
exposure during handling at CoreLabs. Aliquots we received were in identical tubes with 
uniform labels. All aliquots were labeled as being 250 uL, however, we found that the 
actual recoverable volume in each tube varied, with some as low as 100 μL; all data 
reported here are from aliquots with at least 140 μL. 
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Plate position effects.  
To assess whether plate position affects apparent PrP levels in ELISA, we ran two whole ELISA 
plates loaded with technical replicates of the same CSF sample (v1209 with 0.03% CHAPS). 
One plate was loaded with a single channel pipette taking 29 minutes (Fig. S2A-B) and the 
other was loaded with a multichannel pipette taking 11 minutes (Fig. S2C-D). A visually subtle, 
yet significant (P = 1.5e-14), decline in apparent PrP level is seen across the plate. For 
instance, in Fig. S2A, the ten replicates loaded last (wells G9-H6) are on average 22% lower 
than the ten replicates loaded first (wells A11-B8). Adjustment based on the standard curves 
abolishes this slope, and reduces the CV among technical replicates (Fig S2B and D).  
 
Spike recovery experiments. 
While we ultimately achieved 90.5% recovery of recombinant human PrP spiked into CSF, this 
successful outcome was preceded by a number of experiments that usefully illuminate 
constraints of working with both the BetaPrion ELISA assay and CSF PrP as an analyte. In our 
first experiment, recombinant full-length human PrP with concentration orthogonally established 
by amino acid analysis (AAA) was spiked into two CSF samples previously established to have 
high and low baseline PrP. Compared to the expected recovery, the recombinant protein gave a 
much higher signal than expected, with 392-451%, over-recovery (Figure S3A). This surprising 
finding suggested to us that the concentration of PrP in kit standards may be lower PrP in 
practice than their stated concentration. To test this hypothesis, we directly compared the kit 
standard curve to a matched standard curve prepared with our recombinant PrP. This 
experiment confirming that kit standards appeared lower than AAA-quantified PrP standards by 
a factor of roughly 4 (Figure S3B). We conclude that kit standards, while technically 
reproducible, may most usefully inform relative rather than absolute quantification of PrP. 
 
We next attempted to assess spike recovery in an internally consistent system by comparing 
recombinant PrP spiked into CSF to a recombinant PrP standard curve. We diluted recombinant 
PrP in CSF, then serially diluted into additional CSF to create a five-point series. The series of 
samples was re-frozen and measured by ELISA the next day. Under these intensive handling 
conditions, we observed only ~50% recovery even though the samples contained 0.03% 
CHAPS (Figure S3C). We hypothesized that the CHAPS additive, while helpful, could not fully 
protect against the high levels of plastic exposure involved in serial dilution of CSF. To test this 
hypothesis, we redid the experiment in C with special attention to protecting PrP from plastic 
adsorption. Recombinant PrP was diluted in blocking to prepare a series of solutions at 100x the 
desired final concentrations of points in the spike series. These samples were then added to 
CSF aliquots at a 1:100 concentration, and used in a same-day ELISA experiment. With this 
level of attention to plastic exposure and the elimination of an additional freeze-thaw cycle 
relative to the standard curve, PrP was preserved near expected levels with 90.5% recovery 
observed (Figure S3D).  
 
Finally, to assess recovery from a different angle, we titrated a high-PrP CSF sample into a low-
PrP CSF sample at varying ratios, again ensuring minimal and consistent CSF handling. Under 
these conditions, we observed linear and proportional recovery of PrP (Figure S3E). These 
experiments provide additional evidence that the quality of PrP measurement afforded by the 
BetaPrion ELISA assay is dependent on appropriate sample processing.  
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CSF aliquot size and PrP loss. 
We observed that when working with experimental aliquots of CSF, lower volume aliquots 
appeared to have consistently lower PrP levels (Figure S5A). This effect is likely due to 
increased exposure of the sample to plastic due to the higher surface area to volume ratio in the 
polypropylene storage tube. This explanation would be consistent with observed PrP loss 
across multiple regimens of plastic exposure (see Figure 2). Notably, while aliquot size 
profoundly impacts PrP recovery from small (< 100 uL) aliquots, it does not appear to impact 
PrP levels in substantially larger CSF volumes. When comparing 1, 3 and 5 mL draws of a 
pooled CSF sample into identical 5 mL syringes, we did not see a difference in measured PrP 
(Figure S5B). The cylindrical shape of the syringe could also contribute to this finding, as the 
surface-area-to-volume ratio difference between different syringe volumes is less dramatic than 
that for very small sub-aliquots. These data have clinical implications: while downstream sub-
aliquotting and storage can impact PrP levels, different syringe volumes during LPs performed 





Collaborator N Diagnosis Description 
Steven Arnold 18 Alzheimer disease and 
MCI-SNAP 
Placebo-treated controls from a randomized trial 
monitoring effects of metformin on CSF 
biomarkers29. 8-11 week test-retest. Samples 
were handled uniformly (see Supplementary 
Discussion) and were centrifuged prior to 
freezing. 
MGH MIND Tissue 
Bank 
27 NPH, C. dificile, 
herpes simplex 
Large volume assay development samples from 
NPH patients (N=9), test-retest lumbar drains 
(N=18), and lumbar-thoracic gradient samples 
(N=8). Samples were centrifuged for 10 minutes 
at 2,000xG after receipt in our lab. 
Kathryn Swoboda 28 Phenylketonuria Segawa syndrome (GCH1 loss of function) 
patients who received either placebo or 
sapropterin dihydrochloride in a trial monitoring 
effects on CSF biomarkers. 5-25 week test-
retest. Samples were centrifuged for 10 minutes 
at 2,000xG after receipt in our lab. 
Piero Parchi 34 Symptomatic prion 
and non-prion 
dementias 
Dementia patients referred to the CJD Reference 
Center at University of Bologna due to suspected 
prion disease. Samples are autopsy-confirmed 
positive or negative for prion disease. Prion 
samples include sporadic and genetic. Prior to 
arriving at Dr. Parchi's lab from referring 
physicians, samples were variably centrifuged or 
not, and variably shipped frozen, cold, or at room 
temperature. Samples not marked as previously 
centrifuged were centrifuged for 10 minutes at 
2,000xG after receipt in our lab. 
Inga Zerr 29 Symptomatic prion 
and non-prion 
dementias 
Dementia patients referred to the CJD Reference 
Center at University of Göttingen due to 
suspected prion disease. Samples are autopsy-
confirmed positive or negative for prion disease. 
Prion samples include sporadic and genetic. 
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Samples were centrifuged for 10 minutes at 
2,000xG after receipt in our lab. These samples 
were received after the data in Figure 1 were 
generated, so we added 0.03% CHAPS prior to 
sub-aliquotting and ELISA. 
Henrik Zetterberg 20 Cognitive impairment Patients with undiagnosed cognitive impairment 
and normal levels of CSF tau, phospho-tau, and 
amyloid beta. Samples were centrifuged for 10 
minutes at 2,000xG after receipt in our lab. 
Michael 
Geschwind 
61 Symptomatic and pre-
symptomatic genetic 
prion disease 
Participants with PRNP mutations in the Early 
Diagnosis of Human Prion Disease study at 
UCSF49. The cohort includes N=61 samples from 
N=40 distinct individuals (28 pre-symptomatic 
and 12 symptomatic), with 1 to 5 samples per 
person collected at intervals ranging from 2 
months to 6 years. Mutations represented 
include P102L (N=4 individuals), D178N (N=6), 
E200K (N=16), and ten other mutations (details 
omitted to protect patient privacy), including five 
with literature evidence for high penetrance and 
five without (see companion paper by Minikel et 
al). These samples were received after the data 
in Figure 1 were generated, so we added 0.03% 
CHAPS prior to sub-aliquotting and ELISA. 
Samples were never centrifuged. 
TOTAL 225   
 
Table S1. CSF samples analyzed. 
Abbreviations: normal pressure hydrocephalus (NPH); mild cognitive impairment with suspected non-
amyloid pathology (MCI-SNAP). 





































































































Figure S1. The BetaPrion Human PrP ELISA kit quantifies PrP in a technically reproducible and 
sensitive manner.  
A) Consistent dilution linearity was observed within the assay’s stated dynamic range of 1 – 20 ng/mL 
PrP, providing reassurance that this technique can be used to compare PrP levels across samples even 
where these levels differ by one log. B) Five replicates of the kit’s internal six-point standard curve, 
reconstituted from lyophilized standards, were run in parallel on one plate. Across the dynamic range of 
the assay, the coefficient of variation falls below 10% for all points and well below the 20% FDA 
recommended limit in standard variability for ligand-binding assays.  
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Multichannel loading, adjusted based on standard cur ves. CV: 6.9%D
 
Figure S2. Plate position effects.  
Computed PrP levels for standard curves (red), kit controls (gray), or the CSF sample (blue) in two whole 
plates loaded with technical replicates of the same CSF sample (v1209 with 0.03% CHAPS) using either 
a single channel pipette (A-B) or a multichannel pipette (C-D). Displayed are the unadjusted PrP values 
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(A and C) or the PrP values after adjustment based on the difference between the standard curves at the 
beginning and end of the plate (B and D). See supplementary discussion for further interpretation. 
 



























high PrP sample − v1205.6 at 1:100






































































































high PrP sample − v1205.6 at 1:100
























































Figure S3. Spike recovery experiments. 
A) In-house produced full-length recombinant human prion protein, quantified by amino acid analysis 
(AAA) was spiked into two CSF samples previously established to have high and low baseline PrP. 
Recombinant PrP was over-recovered by 392-451% when compared to kit standards. B) A recombinant 
standard curve was prepared from AAA-quantified recombinant huPrP to match the nominal 
concentrations of each of the six points on the BetaPrion kit standard curve. Direct comparisons of the 
two series by ELISA showed the recombinant curve to be contain roughly 4x greater PrP at each point. C) 
Recombinant huPrP was measured according to a recombinant PrP standard curve. Recombinant PrP 
was diluted in CSF, then serially diluted into additional CSF to create a five-point series. The series of 
samples was re-frozen and measured by ELISA the next day. Under these conditions we observed 50.0% 
and 42.5% recovery for two different samples. D) The experiment in C was redone with the following 
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modifications. Recombinant PrP was diluted directly in the initial aliquot tube with blocking buffer (5% 
BSA and 0.05% Tween-20 in PBS, filtered prior to use). It was further diluted in blocking buffer to prepare 
a series of solutions at 100x the desired final concentrations of points in the spike series. These samples 
were then added to CSF aliquots at a 1:100 concentration. These samples were then diluted in blocking 
buffer to their final plating concentration and measured in a same-day ELISA experiment. Under these 
conditions we observed 90.2% recovery. E) A high-PrP CSF sample (sample A) was titrated into a low-
PrP CSF sample at varying ratios, with minimal CSF handling. We observed linear recovery of PrP. See 
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Figure S4. Candidate explanations for variability in CSF PrP levels.  
 
A) Within cohorts of individuals referred with a possible diagnosis of prion disease (Zerr and Parchi 
cohorts), PrP levels are lower in individuals with prion disease than in individuals with other diagnoses. 
PrP levels in sporadic prion disease CSF average 42% of non-prion samples (P = 0.0001, Kolmogorov-
Smirnov test) and in genetic prion disease CSF average 19% of non-prion samples (P = 2.6e-6, 
Kolmogorov-Smirnov test). B) Among individuals with a PRNP mutation (Geschwind cohort), PrP levels in 
symptomatic individuals average 53% of those in pre-symptomatic individuals (P = .001, Kolmogorov-
Smirnov test). C) CSF PrP levels vary dramatically between different cohorts in our study (P = 8.0e-6, 
Type I ANOVA). D) CSF PrP is positively correlated with age (r = 0.47, P = 1.9e-9, Spearman rank test), 
although among our samples age is confounded with cohort, diagnosis, and likely with other unobserved 
variables, so it is unclear whether this correlation is biologically meaningful. E) CSF PrP does not differ 
between men and women (P = 0.31, Kolmogorov-Smirnov test). F) CSF PrP exhibits no lumbar-thoracic 
gradient within ~30 mL intrathecal CSF drips. From each of three individuals with normal pressure 
hydrocephalus, 29-32 mL of intrathecal CSF was collected via drip in 4 polystyrene tubes of 7-8 mL each, 
with "1" being the first tube and "4" being the final tube. Because CSF from further up the spinal column is 
expected to drain downward as CSF is removed, "1" represents the most lumbar CSF while "4" is the 
most thoracic. PrP exhibits no trend across tubes (P = 0.81, linear regression). G) CSF PrP likewise 
exhibits no lumbar-thoracic gradient when ~20 mL of CSF is drawn using gentle aspiration with a 24G 
Sprotte needle. Approximately 5 mL of CSF was drawn in each of four syringes; again, "1" is the most 
lumbar and "4" is the most thoracic. These samples included individuals diagnosed with Alzheimer's 
disease, Parkinson's disease, and undiagnosed individuals. PrP exhibits no trend across syringes (P = 
0.93, linear regression). 
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Figure S5. Additional evidence for loss of PrP to plastic adsorption. 
A) Differently sized aliquots of sample v1187 appear to have different PrP levels. Each dot is the mean, 
and line segment the 95% CI, of two technical replicates on the same plate. These samples did not 
contain CHAPS. B) A pooled CSF standard (STD) was warmed to 37°C and various volumes (1 mL, 3 
mL, or 5 mL) were drawn into identical 5 mL syringes using a 24G Sprotte needle and allowed to sit for 15 
minutes before ejection into tubes, centrifugation, and aliquotting. Samples were handled identically 
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except for the volume drawn into the syringe. See supplementary discussion. C) After aliquotting and 
freeze/thaw, CSF samples were diluted into blocking buffer neat (black) or after addition of 0.03% CHAPS 
(final concentration) to the original storage tube. Addition of CHAPS resulted in a 75% increase in 
apparent PrP level. See supplementary discussion. D and E) Replication of the findings from Figure 1A-B. 
The data in Figure 1 were generated using CSF samples from two different individuals; to rule out the 
possibility that some other inter-individual difference, rather than CHAPS, explained the difference in 
plastic loss, we repeated the experiment but with a single CSF sample divided into two halves which were 
then aliquotted without (D) or with (E) 0.03% CHAPS, subjected to the same battery of perturbations and 
plated at the same dilution. Because CHAPS increases overall PrP recovery, some replicates in (E) are at 
the upper limit of quantification; nevertheless, the results recapitulate Figure 1. F) 1 mg/mL (final 
concentration) BSA, or PBS as a control, were added to CSF sample 165.2, which had an initial total 
protein level at the low end of the distribution of our samples (measured at 0.22 mg/mL with PBS), 
bringing it up to a total protein level at the high end of our samples (measured at 1.15 mg/mL after BSA 
spike-in). BSA or PBS were added after centrifugation but prior to aliquotting at 40 uL and re-freezing. 4 
tubes of each sample were subsequently thawed and diluted into blocking buffer for analysis. Total 
recovery of PrP is increased in the BSA-spiked samples, analogous to panel B, although BSA is less 





1 2 3 4 5 6 7 8 9


































































Figure S6. Hemoglobin in test-retest samples. 
Overlaid are PrP levels (blue, same data as shown in Figure 3) and hemoglobin levels (red) in test-retest 
samples. PrP exhibited good test-retest reliability (CV=13%) despite dramatic variation in hemoglobin 
(CV=136%), providing further evidence that blood contamination does not influence CSF PrP level. 
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Figure S7. Test-retest reliability of CSF PrP in additional cohorts.  
Test-retest CSF PrP levels in A) metformin trial participants (Arnold) over 8-11 weeks, with mean 
CV=13% (same data from Figure 3 but plotted normalized to the PrP level at the first visit); B) sapropterin 
dihydrochloride trial participants (Swoboda) over 5-25 weeks, with mean CV=33%, C) NPH lumbar drains 
(MGH MIND Tissue Bank) over 1 day to 4 months, with mean CV=40%, D) pre-symptomatic and E) 
symptomatic PRNP mutation carriers (Geschwind) over 2 months to 6 years, each with mean CV=34%. 
The repeated 34% is not an error: the mean CVs in (D) and (E) happen to be the same (34.28% and 
34.25%). See supplementary discussion for details on sample handling in these cohorts. 








Figure S8. Protocol for collection of CSF for PrP measurement. 
We have incorporated our findings into the above protocol, which we are using to collect test-retest CSF 
for the purposes of PrP measurement in our ongoing clinical study.  
